Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

PSTI 3.72 +0.04 (1.09%)
price chart
Pluristem Therapeutics (PSTI) in Focus: Stock Surges 20.4%
Pluristem Therapeutics, Inc. (PSTI - Snapshot Report) was a big mover last session, as the company saw its shares rise more than 20% on the day.
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4%
Pluristem Therapeutics, Inc. (PSTI - Snapshot Report) was a big mover last session, as the company saw its shares rise over 7% on the day.
Biotech Bulls Grab Market Attentions: Exelixis, Inc. (NASDAQ:EXEL), Pluristem ...
Shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) [Detail Analytic Report] jumped over 8.3% in premarket trading session on Thursday as is speed up time to market authorization for its first sign.
Market News: The Madison Square Garden Co (NASDAQ:MSG), Pluristem ...
Pluristem Therapeutics Inc. (NASDAQ:PSTI) shares gained more than 22% Wednesday, a day after it was the subject of an updated coverage report by Acceleron Equity Research.
Best Portfolio of Healthcare sector: Pluristem Therapeutics Inc. (PSTI ...
In Healthcare sector, Pluristem Therapeutics Inc. (NASDAQ:PSTI) has shown an uptrend of +23.44% in past 5 days with YTD performance of +34.80% and 3-month performance up +15.81%.
Mid-Day Changers: Uroplasty, Inc. (UPI), Pluristem Therapeutics, Inc. (PSTI ...  WallStreet Scope
Morning Alert - Pluristem Therapeutics (PSTI),Alpha Natural Resources, (ANR ...  Techsonian (press release)
Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel ...
This is the second regulatory approval for the company's 3D cell manufacturing process, having received approval in Germany last January.
Related articles »  
Biotech Risers: CorMedix (CRMD), Omeros (OMER), Pluristem Therapeutics ...
CorMedix Inc. (NYSEMKT:CRMD) declared that the U.S. Food and Drug Administration (FDA) has designated the company's lead product applicant, Neutrolin´┐Ż Catheter Lock Solution, as a Qualified Infectious Disease Product (QIDP) for oncology, ...
Stocks Underperform for the Week: GenMark Diagnostics Inc , Pluristem ...
Pluristem Therapeutics Inc. (NASDAQ:PSTI) has dropped 3.94% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 9.39% in the past 4 weeks.
Will Pluristem Therapeutics (PSTI) Crush Estimates at Its Next Earnings Report?
After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company's earnings prospects.
Related articles »  
Pluristem Therapeutics Inc. (PSTI) news: Pluristem's Preeclampsia Effort ...
The power of the placenta rings truer than ever in an upcoming therapeutic indication planned by Pluristem Therapeutics, Inc. (NASDAQ:PSTI) using PLX cell therapy for treating pregnant women with preeclampsia, a leading cause of maternal and infant ...
Related articles »